Fig. 4From: Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatmentDevelopment of new personalized antitumor therapies for cancer patients. Due to the importance of CSC secretome in tumor development, chemoresistance and relapse, the new therapies need to combine different TME and CSC inhibitors. Robust biomarkers are required to identify the patients that will benefit from these treatmentsBack to article page